[go: up one dir, main page]

DE69637587D1 - Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen - Google Patents

Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen

Info

Publication number
DE69637587D1
DE69637587D1 DE69637587T DE69637587T DE69637587D1 DE 69637587 D1 DE69637587 D1 DE 69637587D1 DE 69637587 T DE69637587 T DE 69637587T DE 69637587 T DE69637587 T DE 69637587T DE 69637587 D1 DE69637587 D1 DE 69637587D1
Authority
DE
Germany
Prior art keywords
receptors
metabotropic glutamate
treatment
neurological
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69637587T
Other languages
English (en)
Inventor
Forrest H Fuller
Karen J Krapcho
Lance G Hammerland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of DE69637587D1 publication Critical patent/DE69637587D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69637587T 1995-07-26 1996-07-25 Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen Expired - Fee Related DE69637587D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US152695P 1995-07-26 1995-07-26
PCT/US1996/012336 WO1997005252A2 (en) 1995-07-26 1996-07-25 Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases

Publications (1)

Publication Number Publication Date
DE69637587D1 true DE69637587D1 (de) 2008-08-21

Family

ID=21696494

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69637587T Expired - Fee Related DE69637587D1 (de) 1995-07-26 1996-07-25 Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen

Country Status (10)

Country Link
US (3) US5981195A (de)
EP (1) EP0783577B1 (de)
JP (2) JPH10507934A (de)
AT (1) ATE400653T1 (de)
AU (1) AU710128B2 (de)
CA (1) CA2200606A1 (de)
DE (1) DE69637587D1 (de)
ES (1) ES2308779T3 (de)
IL (2) IL120424A0 (de)
WO (1) WO1997005252A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE400653T1 (de) * 1995-07-26 2008-07-15 Astrazeneca Ab Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen
AU750179B2 (en) * 1995-07-26 2002-07-11 Astrazeneca Ab Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
US6084084A (en) * 1996-02-21 2000-07-04 Nps Pharmaceuticals, Inc. Human metabotropic glutamate receptor
WO1999021992A2 (en) * 1997-10-23 1999-05-06 Ganimed Pharmaceuticals Gmbh Nucleic acid molecules encoding a glutamate receptor
EP1066325A1 (de) * 1998-04-03 2001-01-10 Nps Pharmaceuticals, Inc. G-protein-gekoppelte rezeptoren und chimären gabab rezeptoren
US7262280B1 (en) 1998-04-03 2007-08-28 Nps Pharmaceuticals, Inc. G-protein fusion receptors and constructs encoding same
CA2337438A1 (en) * 1998-07-13 2000-01-20 Parkash S. Gill Novel inhibitors of angiogenesis and tumor growth
AU778063C (en) 1999-06-02 2005-12-15 Astrazeneca Ab Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
US6534287B1 (en) 1999-10-25 2003-03-18 Nps Pharmaceuticals, Inc. Human metabotropic glutamate receptor
DE60139458D1 (de) * 2000-02-04 2009-09-17 Lexicon Pharmaceuticals Inc Neue menschliche g-protein gekoppelten rezeptoren und dafür kodierende polynucleotide
AU2001249569B2 (en) * 2000-03-28 2006-05-04 Lexicon Pharmaceuticals, Inc. Novel human 7tm proteins and polynucleotides encoding the same
EP1305341A1 (de) 2000-07-21 2003-05-02 Merck & Co., Inc. Melanin-konzentrierender hormonrezeptor aus dem hund
CA2424546A1 (en) * 2000-10-03 2002-04-11 Nps Pharmaceuticals, Inc. G-protein fusion receptors and chimeric gabab receptors
MXPA03005428A (es) * 2000-12-22 2003-09-10 Wyeth Corp Nuevas proteinas y moleculas de acido nucleico moduladoras del receptor de glutamato y uso de las mismas.
US20070003980A1 (en) * 2001-03-27 2007-01-04 Woods Daniel F Efficient methods to isolate effectors of proteins involved in olfactory or chemosensory pathways and efficient methods to use these effectors to alter organism olfaction, chemosensation, or behavior
US20100248268A1 (en) * 2001-03-27 2010-09-30 Woods Daniel F Methods to utilize invertebrate chemosensory proteins for industrial and commercial uses
CA2449011A1 (en) 2001-05-31 2002-12-05 Merck & Co., Inc. Rhesus monkey, dog and ferret melanin-concentrating hormone type 2 receptor
JP4356454B2 (ja) 2001-10-23 2009-11-04 味の素株式会社 新規グルタミン酸受容体とその利用
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
RU2315059C2 (ru) 2002-07-23 2008-01-20 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик (С.К.Р.А.С.) Аналоги грелина
TWI331922B (en) 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
US20050186658A1 (en) * 2003-10-17 2005-08-25 Nps Pharmaceuticals, Inc. Chimeric metabotropic glutamate receptors and uses thereof
SI1937262T1 (sl) 2005-09-29 2019-09-30 Ipsen Pharma Spojina za uporabo pri zdravljenju gastrointestinalne dismotilitete
TW200916113A (en) 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
BR122022007044B1 (pt) * 2011-06-24 2023-11-14 Novartis Ag Composições farmacêuticas que compreendem uma proteína de gpcr quimérica, proteína de gpcr quimérica, molécula de ácido nucleico, e vetor
WO2013120082A1 (en) 2012-02-10 2013-08-15 Kassab Ghassan S Methods and uses of biological tissues for various stent and other medical applications
WO2014124356A2 (en) 2013-02-11 2014-08-14 Cook Medical Technologies Llc Expandable support frame and medical device
AU2018256436B2 (en) 2017-04-19 2024-12-05 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
EP3755349A4 (de) 2018-02-21 2021-11-17 Board of Regents, The University of Texas System Verfahren zur aktivierung und expansion von natürlichen killerzellen und deren verwendungen

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4859609A (en) * 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US5030576A (en) * 1986-04-30 1991-07-09 Genentech, Inc. Receptors for efficient determination of ligands and their antagonists or agonists
NZ240921A (en) * 1990-12-12 1994-06-27 Zymogenetics Inc G protein coupled glutamate receptor (neurotransmitters), recombinant production
WO1992020642A1 (en) * 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
US5858684A (en) * 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
CA2094987A1 (en) * 1992-05-01 1993-11-02 James P. Burnett, Jr. Human glutamate receptor proteins and associated dna compounds
IL105587A0 (en) * 1992-05-08 1993-09-22 Lilly Co Eli Human metabotropic glutamate receptor and related dna compounds
DE69333527T2 (de) * 1993-02-23 2005-06-16 Brigham & Women's Hospital, Inc., Boston Calciumrezeptoraktive moleküle
US5521297A (en) * 1993-06-04 1996-05-28 Salk Institute Biotechnology/Industrial Associates Nucleic acids encoding human metabotropic glutamate receptors
WO1995008627A1 (en) * 1993-09-20 1995-03-30 Ciba-Geigy Ag Human metabotropic glutamate receptor subtypes (hmr4, hmr6, hmr7) and related dna compounds
EP1275635A1 (de) * 1994-10-21 2003-01-15 Nps Pharmaceuticals, Inc. Kalzium-Rezeptor aktive Verbindungen
TW502026B (en) * 1995-06-20 2002-09-11 Zeneca Ltd Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates
ATE400653T1 (de) * 1995-07-26 2008-07-15 Astrazeneca Ab Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen
US6084084A (en) * 1996-02-21 2000-07-04 Nps Pharmaceuticals, Inc. Human metabotropic glutamate receptor
US6288610B1 (en) * 1998-03-19 2001-09-11 Fujitsu Limited Method and apparatus for correcting signals, apparatus for compensating for distortion, apparatus for preparing distortion compensating data, and transmitter
MXPA03005428A (es) * 2000-12-22 2003-09-10 Wyeth Corp Nuevas proteinas y moleculas de acido nucleico moduladoras del receptor de glutamato y uso de las mismas.
BE1014570A4 (fr) * 2002-01-11 2004-01-13 Sonaca Sa Procede de fabrication d'une structure cannelee et structure obtenue par ce procede.

Also Published As

Publication number Publication date
WO1997005252A2 (en) 1997-02-13
EP0783577B1 (de) 2008-07-09
JPH10507934A (ja) 1998-08-04
WO1997005252A3 (en) 1997-05-22
AU710128B2 (en) 1999-09-16
EP0783577A1 (de) 1997-07-16
US5981195A (en) 1999-11-09
JP2007006893A (ja) 2007-01-18
US20030113873A1 (en) 2003-06-19
US6534289B1 (en) 2003-03-18
IL120424A (en) 2008-12-29
AU6602296A (en) 1997-02-26
ES2308779T3 (es) 2008-12-01
ATE400653T1 (de) 2008-07-15
CA2200606A1 (en) 1997-02-13
IL120424A0 (en) 1997-07-13

Similar Documents

Publication Publication Date Title
DE69637587D1 (de) Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen
ATE402698T1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE58299T1 (de) Geraet zur behandlung neurovegetativer stoerungen.
DE69535498D1 (de) Verfahren zur behandlung vaskulärer kopfschmerzen
DE69617235D1 (de) Epoxysteroide aldosteronantagonist und angiotensin ii rezeptor antagonist kombinationstherapie zur behandlung von congestivem herzversagen
DE60022050T2 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems
DE69611251D1 (de) Hydroperoxeicosatetraensäure derivate enthaltende zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges
DE69632743D1 (de) Verfahren zur regulierung des vagaltonus
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
ATE362363T1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
ATE323482T1 (de) Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten
ATE403437T1 (de) Lfa-1 antagonisten und tnf-alpha antagonisten zur behandlung von rheumatoiden arthritis
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE69739734D1 (de) Guanylhydrazone die nützlich sind zur behandlung von mit t-zellen verbundenen krankheiten
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
DE69524623D1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE304855T1 (de) Verwendung von olanzapin zur behandlung von mentalen erkrankungen verursacht durch zerebrovaskuläre erkrankungen
DE60323592D1 (de) Verfahren zur Identifizierung von Agenzien zur Behandlung von Anfällen, neurologischen Erkrankungen, Endokrinopathien und hormonalen Erkrankungen
ATE484294T1 (de) Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen
ATE368110T1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
ATE222491T1 (de) Melatonin-derivate zur verwendung in der behandlung von schlafstörungen
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee